Zobrazeno 1 - 10 of 14 pro vyhledávání: '"Ahmad Ghorab"'
2
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia
Autor: Naval Daver, Courtney D. DiNardo, Ahmad Ghorab, Farhad Ravandi, Allyson Price, Tapan M. Kadia, Naveen Pemmaraju, Gautam Borthakur, Xuemei Wang, Dai Chihara, Fevzi Firat Yalniz, Koji Sasaki, Hagop M. Kantarjian, Keyur P. Patel, Ghayas C. Issa, Jorge E. Cortes, Hyunsoo Hwang, Iman Abou Dalle
Publikováno v: Blood Cancer Journal, Vol 10, Iss 5, Pp 1-10 (2020)
Blood Cancer Journal
FLT3-ITD mutations in newly diagnosed acute myeloid leukemia (AML) are associated with worse overall survival (OS). FLT3-ITD diversity can further influence clinical outcomes. Addition of FLT3 inhibitors to standard chemotherapy has improved OS. The
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba46005ee381f47edb5702b80561b33a
http://link.springer.com/article/10.1038/s41408-020-0318-1
Zobrazit plný text záznamu
5
Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies
Autor: Talha Badar, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Aref Al-Kali, Mark R. Litzow, Jeanne Palmer, Mithun Vinod Shah, James M. Foran, Ahmad Ghorab, Michelle Elliot
Publikováno v: Blood. 138:3688-3688
Introduction: Historically, clinical outcome of patients with myelodysplastic syndrome (MDS), progressing on hypomethylating agents (HMA; azacitidine or decitabine) has been dismal with median overall survival (OS) of less than 6 months (Jabbour et a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8a6b6e8cfe80b9a5f799f82022bc82bc
https://doi.org/10.1182/blood-2021-150626
Zobrazit plný text záznamu
7
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib
Autor: Sattva S. Neelapu, Maria Badillo, Dongfeng Zeng, Liang Zhang, L. J. Medeiros, Richard E. Champlin, Luis Fayad, Linghua Wang, Michael L. Wang, Tiejun Gong, Ahmad Ghorab, Jorge E. Romaguera, Shaojun Zhang, Krystle Nomie, Preetesh Jain, Frederick B. Hagemeister, Makhdum Ahmed, Nathan Fowler, Shaoying Li, Wendy Chen, Rashmi Kanagal-Shamanna, Chi Young Ok
Publikováno v: British journal of haematology. 183(4)
Long term outcomes and mutations in patients with mantle cell lymphoma (MCL) who discontinued ibrutinib have not been described. Using deep targeted next generation sequencing, we performed somatic mutation profiling from 15 MCL patients (including 5
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::863855842e6d159cd79274eb9b0f9950
https://pubmed.ncbi.nlm.nih.gov/30175400
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje